Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
WD repeat domain 33 (WDR33)
- Target
- WDR33
- Molecular classification
- WD repeat domain-containing protein, Component of the cleavage and polyadenylation specificity factor complex (CPSF), Protein scaffold, Beta propeller structural family
01
Overview
WD repeat domain 33 (WDR33) is a highly conserved nuclear protein that acts as a central subunit of the cleavage and polyadenylation specificity factor (CPSF) complex, directly binding and recognizing the AAUAAA polyadenylation signal in pre-mRNA to facilitate 3′ end processing and mRNA maturation. The full-length protein contains multiple WD repeat domains and localizes to the nucleus, participating in the assembly of active RNA processing complexes. Alternative transcript variants generate non-canonical isoforms with additional roles, including modulation of the innate immune response via STING interaction. As a member of the WD repeat protein family, WDR33 forms stable protein-protein interaction platforms crucial for a variety of essential cellular processes, though it is not a direct therapeutic target or clinical biomarker at present.
- Other names
- WD repeat-containing protein 33wdr33FLJ11294-like
02
Mechanism of action
Not applicable (no drugs known to target WDR33; it acts as part of a multiprotein complex mediating RNA 3′ end processing)
03
Biological functions
Recognition of AAUAAA polyadenylation signal in pre-mRNAAssembly of 3′ end processing machinery for mRNA maturation (cleavage and polyadenylation)Regulation of gene expression at the level of mRNA processingPotential roles in cell cycle progression, signal transduction, apoptosis, and gene regulation (as typical for WD repeat protein family members)Atypical isoforms may regulate innate immune responses via interaction with STINGPutative roles in cytodifferentiation and/or DNA recombination
04
Disease associations
No direct, well-established roles as a therapeutic target in specific disease areasThe WD repeat protein family has indirect associations with genetic diseases due to their widespread roles in cellular pathwaysThere is no clear or direct link with cancer, inflammation, or neurodegenerative disease for WDR33 itself as of current evidence
05
Safety considerations
Not applicable (WDR33 is not a current therapeutic target; no associated safety concerns described in literature)
06
Interacting drugs
None known (no approved or investigational drugs specifically target WDR33)
07
Biomarkers
None established (not used clinically as a biomarker for patient selection or efficacy monitoring)
Beyond the preview
Go deeper on WD repeat domain 33 (WDR33).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on WD repeat domain 33 (WDR33).